SCHEMBL10131979

SCHEMBL10131979

CN[C@H]1CCCN(CC(C)=O)C1=O

nearest known ligand 0.43

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ACE P12821 9/20 0.43
F10 P00742 7/20 0.41
MMP1 P03956 2/20 0.38
MMP3 P08254 2/20 0.38
BDKRB2 P30411 1/20 0.38
MME P08473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10131968 1.00 ACE (0.43) ACEF10MMP1MMP3BDKRB2
SCHEMBL10132002 1.00 ACE (0.43) ACEF10MMP1MMP3BDKRB2
SCHEMBL12253675 0.95 MMP1 (0.42) ACEF10MMP1MMP3BDKRB2
SCHEMBL10131994 0.95 MMP1 (0.42) ACEF10MMP1MMP3BDKRB2
SCHEMBL10331834 0.95 MMP1 (0.42) ACEF10MMP1MMP3BDKRB2
SCHEMBL16838509 0.94 ACE (0.43) ACEF10MMP1MMP3BDKRB2
SCHEMBL10131998 0.90 ACE (0.41) ACEF10MMP1MMP3BDKRB2
SCHEMBL12253676 0.90 ACE (0.41) ACEF10MMP1MMP3BDKRB2
SCHEMBL10331848 0.90 ACE (0.41) ACEF10MMP1MMP3BDKRB2
SCHEMBL10065856 0.87 ACE (0.56) ACEF10MME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012603-B2 Peptides that block the binding of IgG to FcRn BIOGEN IDEC HEMOPHILIA INC. (US) 2015-04-21 US disclosed
US-9012603-B2 Peptides that block the binding of IgG to FcRn BIOGEN IDEC HEMOPHILIA INC. (US) 2015-04-21 US disclosed
US-8906844-B2 Immunomodulatory peptides BIOGEN IDEC HEMOPHILIA INC. (US) 2014-12-09 US disclosed
US-8906844-B2 Immunomodulatory peptides BIOGEN IDEC HEMOPHILIA INC. (US) 2014-12-09 US disclosed
US-8101186-B2 Peptides that block the binding of IgG to FcRn SYNTONIX PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-8101186-B2 Peptides that block the binding of IgG to FcRn SYNTONIX PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-20110230639-A1 IMMUNOMODULATORY PEPTIDES SYNTONIX PHARMACEUTICALS INC. (US) 2011-09-22 US disclosed
US-20110230639-A1 IMMUNOMODULATORY PEPTIDES SYNTONIX PHARMACEUTICALS INC. (US) 2011-09-22 US disclosed
US-20110059889-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn SYNTONIX PHARMACEUTICALS, INC. 2011-03-10 US disclosed
US-20110059889-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn SYNTONIX PHARMACEUTICALS, INC. 2011-03-10 US disclosed
WO-2009020867-A2 IMMUNOMODULATORY PEPTIDES SYNTONIX PHARMACEUTICALS, INC. (US) 2009-02-12 WO disclosed
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn BIOGEN HEMOPHILIA INC. 2007-11-01 US disclosed
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn BIOGEN HEMOPHILIA INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059889-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn FCGRT, FCGR3B, FCGR1A ACE 1806/4885F10 148/4885MMP1 3010/4885
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn FCGRT, FCGR3B, FCGR1A ACE 1806/4885F10 148/4885MMP1 3010/4885
US-20110230639-A1 IMMUNOMODULATORY PEPTIDES FCGRT, FCGR3B, FCGR2A ACE 1690/4885F10 415/4885MMP1 2165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.